StackTerminal.Health

BETA
Research compound

This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.

GHRP-2

GHRP-2 is a synthetic hexapeptide growth hormone secretagogue that stimulates GH release by acting on the ghrelin receptor, with moderate effects on cortisol and prolactin levels. It is used to enhance growth hormone secretion, particularly in individuals with GH insufficiency or idiopathic short stature.

growth-hormonerecoverybody-compositionappetite
Evidence last reviewed: 19 Apr 2026
Buy this ingredient← Back
Supplement note
Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Sign in to keep a private note on GHRP-2.
Sign in
Biomarkers studied
Outcomes directly measured across the evidence records below
Hormonal
Growth HormoneCortisol
Evidence
5 records
GH secretion
Normal adults • RCT
PUBMEDModerate

GHRP-2 significantly increased GH levels compared to GHRH alone.

Dose: 0 mgForm: Intravenous
Citation: Tiulpakov et al. (1995). GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers. Clinical Endocrinology.
GH secretion
Children with GH insufficiency and idiopathic short stature • RCT
PUBMEDModerate

GHRP-2 increased GH secretion in children with GH insufficiency and idiopathic short stature.

Dose: 0 mgForm: Intravenous
Citation: Tuilpakov et al. (1995). Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism.
Cortisol secretion
Healthy non-obese male volunteers • RCT
PUBMEDModerate

GHRP-2 stimulated cortisol secretion, influenced by secretagogue type and sex-steroid milieu.

Dose: 0 mg
Citation: Iranmanesh et al. (2010). Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretion. European Journal of Endocrinology.
GH secretion
Young men with experimentally induced hypogonadism • RCT
PUBMEDModerate

GHRP-2 maintained efficacy in stimulating GH release despite hypogonadism.

Dose: 0 mg
Citation: Veldhuis et al. (2009). Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism. European Journal of Endocrinology.
GH secretion
Children with GH insufficiency and idiopathic short stature • RCT
PUBMEDModerate

GHRP-2 significantly increased GH levels compared to GHRH alone.

Dose: 0 mgForm: Intravenous
Citation: Van den Berghe et al. (1997). The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. The Journal of Clinical Endocrinology & Metabolism.
Forms
Intravenous
Commonly used in clinical settings for precise dosing.
Subcutaneous
Preferred for self-administration due to ease of use.

Stacks containing GHRP-2

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.